Know Cancer

forgot password

18 Years
Not Enrolling
Lambert-Eaton Myasthenic Syndrome

Thank you

Trial Information

PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. Patients are
randomized to receive 3,4-diaminopyridine (DAP) or placebo orally 3 times daily for 5 days,
after which treatment is discontinued and patients are observed for at least 24 hours. At
the end of the blinded study, patients may then elect to take open label DAP orally 3 times
daily for 6 months; those who do so are monitored for clinical effects and side effects for
at least 6 months.

Inclusion Criteria


--Disease Characteristics-- Lambert-Eaton myasthenic syndrome (LEMS) based on weakness
that predominates in proximal limb muscles and electromyography (EMG) findings of small
amplitude muscle responses to nerve stimulation, which decrease further during nerve
stimulation at 5 Hz and which increase at least 2-fold after maximum voluntary contraction
of the muscle for 10-20 seconds Quantified Myasthenia Gravis (QMG) clinical score at least
5 --Prior/Concurrent Therapy-- Chemotherapy: No concurrent chemotherapy Endocrine therapy:
Patients receiving immunosuppressants must be on the same dose of medication for at least
3 months prior to study entry Radiotherapy: No concurrent radiotherapy Surgery: No
concurrent surgery Other: Patients receiving cholinesterase inhibitors must discontinue
the medication at study entry if possible, or else be on the same dose of medication for
at least 1 month prior to study entry --Patient Characteristics-- Hematopoietic: No
significant hematologic disease Hepatic: No significant hepatic disease Renal: No
significant renal disease Cardiovascular: No cardiac arrhythmia or significant cardiac
disease Neurologic: No seizure disorder Other: Not pregnant Negative pregnancy test
required of fertile women Effective contraception required of fertile women

Type of Study:


Study Design:

Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment

Principal Investigator

Donald B. Sanders

Investigator Role:

Study Chair

Investigator Affiliation:

Duke University


United States: Federal Government

Study ID:




Start Date:

August 1994

Completion Date:

June 1998

Related Keywords:

  • Lambert-Eaton Myasthenic Syndrome
  • Lambert-Eaton myasthenic syndrome
  • neurologic and psychiatric disorders
  • rare disease
  • Lambert-Eaton Myasthenic Syndrome